Co-introduction of functional CCR2 successfully enhanced in vivo anti-lung cancer reactivity mediated by infused double-transfected effector T cells, notably in the phase immediately after the start of therapeutic infusion, reflecting the increased tumor trafficking activity in response to CCL2. This evidence concerns the gene CCL2 and lung carcinoma.